Physician profile
Bernard J Kulper
NPI 1063499218
$6,820.09
in general payments reported to CMS, 2019-2025
21 companies · $650 in 2025
The $650 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $542 · 2021: $806 · 2022: $2,302 · 2023: $525 · 2024: $1,400 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,575.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $2,010.73 | 2022 | |
| Taiho Oncology, INC. | $1,400.00 | 2024 | |
| Daiichi Sankyo INC. | $940.93 | 2019-2025 | Vanflyta |
| Incyte Corporation | $659.14 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $525.00 | 2023 | Calquence |
| E.R. Squibb & Sons, L.L.C. | $377.12 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $300.00 | 2020 | |
| Medical Device Business Services, INC. | $117.19 | 2019 | |
| Pfizer INC. | $96.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $61.66 | 2019-2022 | |
| Amgen INC. | $59.07 | 2019-2021 | |
| Agios Pharmaceuticals, INC. | $56.35 | 2020 | |
| Merck Sharp & Dohme LLC | $43.57 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.58 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.46 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $29.90 | 2019 | |
| Emd Serono, INC. | $14.98 | 2021 | |
| Global Blood Therapeutics, INC. | $14.61 | 2021 | |
| Eisai INC. | $14.33 | 2022 | |
| Janssen Biotech, INC. | $14.05 | 2020 | |
| Rigel Pharmaceuticals, INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Kulper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.